STML Crosses Above Average Analyst Target
May 29, 2020 at 08:07 AM EDT
In recent trading, shares of Stemline Therapeutics Inc (STML) have crossed above the average analyst 12-month target price of $11.80, changing hands for $11.86/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..